Tysabri® Two-Year Phase III Multiple Sclerosis Clinical Trial Results And Safety Evaluation Published In NEJM

... 0.001) in the annualized relapse rate compared to placebo. TYSABRI treatment also resulted in sustained and statistically significant reductions in brain lesion activity as measured by MRI. The two-year SENTINEL Phase III data also demonstrated that treatment with TYSABRI in addition to AVONEX had a significant effect on disability progression, relapse rate and brain MRI disease activity compared to AVONEX alone... click link for more info. ...